Aldeyra Secures US Orphan Drug Tag For Its Retinitis Pigmentosa Candidate

Trending Investment Opportunities

The FDA has granted orphan drug designation to Aldeyra Therapeutics Inc's ALDX ADX-2191 to treat retinitis pigmentosa (RP).
ADX-2191 is a methotrexate for intravitreal injection.
Methotrexate inhibits dihydrofolic reductase, an enzyme involved in cellular replication and activation.
Price Action: ALDX shares are up 0.56% at $9 during the market session on the last check Wednesday.
Related content: Benzinga's Full FDA Calendar.